Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue

Allarity Therapeutics, Inc.

Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.
Cash balance of $18.5M as of Sept 30, 2024, sufficient to initiate registrational trial toward FDA approval.
Allarity Medical Lab signs external service agreements for DRP and gene expression analysis with multiple biotech firms.
Revenue from lab services reduces overall lab cost base and advances DRP platform in oncology field.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.